Freenome, Inc. Stock

FRNM

US35661P1003

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 18:51:34 28/10/2026 +03			5-day change	1st Jan Change
13.49 ^USD	+3.45%		-7.25%	+0.08%

10-20	Freenome, Inc. Launches SimpleScreenTM Lung And Personalized Cancer Detection Offering With SimpleScreen CRC	CI
10-20	Freenome Launches SimpleScreen Lung Cancer Test	MT

Analysts' recommendations: Freenome, Inc.

08-20	Guggenheim Initiates Freenome at Buy With $21 Price Target	MT
08-18	TD Cowen Initiates Freenome at Buy With $17 Price Target	MT
08-17	Freenome Shares Rise After Jefferies Initiates Coverage	MT
08-17	Jefferies Initiates Freenome at Buy, With $17 Price Target	MT
08-17	BTIG Initiates Freenome at Buy, With $17 Price Target	MT

More recommendations

Press Releases: Freenome, Inc.

10-20	Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option	GL
10-15	Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026	GL
10-11	Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026	GL
08-12	FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test	GL
07-27	FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.	GL

More press releases

News in other languages: Freenome, Inc.

09-30

Abbott lance un test sanguin de dépistage du cancer colorectal développé avec Freenome

More news

Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.

Employees

378

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
27/10/26	$13.04	+2.52%	516,671
26/10/26	$12.72	-0.39%	371,468
23/10/26	$12.77	-2.52%	612,770
22/10/26	$13.10	-6.50%	586,697
21/10/26	$14.01	-0.36%	381,705

End-of-day quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.04USD

Average target price

18.00USD

Spread / Average Target

+38.04%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Freenome, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Freenome, Inc.

Company calendar

Market Cap	1.4B 1.26B 1.16B 1.05B 1.97B 133B 1.99B 13.92B 5.53B 69.76B 5.26B 5.15B 221B	P/E 2026 *	-6.62x	P/E 2027 *	-5.84x
Enterprise Value	1.4B 1.26B 1.16B 1.05B 1.97B 133B 1.99B 13.92B 5.53B 69.76B 5.26B 5.15B 221B	EV / Sales 2026 *	13.7x	EV / Sales 2027 *	12.3x
Free-Float	74.05%	Yield 2026 *	-	Yield 2027 *	-

1 day	+3.26%
1 week	-7.25%
Current month	-17.21%
1 month	-18.45%
3 months	+14.59%
6 months	+16.12%
Current year	+0.08%

1 week	12.48	14.16
1 month	11.63	17.3
Current year	9.95	17.5
1 year	9.95	17.5
3 years	9.95	17.5
5 years	9.95	17.5
10 years	9.95	17.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/2/26 A	Aaron Elliott	Tax	Chief Executive Officer	-71,920	0.0669%
7/20/26 A	Aaron Elliott	Other	Chief Executive Officer	835,791	0.3889%
7/20/26 A	Harlan Waksal	Conversion		-30,000	1.3913%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FREENOME, INC.	+3.45%	-7.25%	+22.10%	-	1.4B
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+2.27%	+1.78%	+12.38%	+83.04%	54.55B
LONZA GROUP AG	-1.01%	+1.09%	+10.56%	+102.38%	53.59B
IQVIA HOLDINGS INC.	+2.74%	+1.01%	+28.10%	+57.72%	44.75B
BEONE MEDICINES AG	+2.47%	-2.89%	+18.44%	+101.10%	41.62B
REVOLUTION MEDICINES, INC.	+1.17%	-3.12%	+223.56%	+925.69%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+27.41%	+46.91%	+106.10%	+93.32%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.34%	-1.07%	+49.07%	+162.93%	38.18B
Weighted average by Cap.	+3.22%	-0.31%	+47.48%	+161.65%

Freenome, Inc. Stock

Stocks

FRNM

US35661P1003

Biotechnology & Medical Research

Valuation: Freenome, Inc.

Chart: Freenome, Inc.

Latest news: Freenome, Inc.

Analysts' recommendations: Freenome, Inc.

Press Releases: Freenome, Inc.

News in other languages: Freenome, Inc.

Quotes and Performance

Price Extremes

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

	2026 *	2027 *
Net sales	102M 91.92M 84.87M 76.96M 144M 9.73B 146M 1.02B 404M 5.1B 384M 376M 16.17B	114M 102M 94.34M 85.55M 160M 10.81B 162M 1.13B 449M 5.67B 427M 418M 17.97B
Net income	-175M -157M -145M -132M -246M -16.63B -249M -1.74B -691M -8.72B -657M -643M -27.65B	-246M -221M -204M -185M -345M -23.34B -349M -2.44B -970M -12.24B -922M -903M -38.8B
Net Debt	-	-